Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing transformative therapies for autoimmune diseases and cancer, has revealed new preclinical findings regarding its investigational drug CLN-978. This innovative CD19xCD3 bispecific T cell engager demonstrated significant B cell depletion both in vitro and in vivo across various autoimmune disorders.
The new data will be showcased at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, Illinois, from October 24 to 29. A poster presentation detailing these findings is scheduled for October 28, from 10:30 a.m. to 12:30 p.m. CT, during Poster Session C (Poster Number 2293).
In addition to the presentation, Cullinan Therapeutics will host a booth (#1074) in the Exhibit Hall, providing an opportunity for attendees to engage with the team and learn more about their ongoing research and development efforts.
The data presented is expected to advance the understanding of CLN-978″s therapeutic potential, particularly in conditions where B cell activity is detrimental, thereby offering hope for new treatment avenues in autoimmune diseases.
As Cullinan Therapeutics continues to explore the implications of these findings, the scientific community will be closely monitoring the outcomes of this research, which could pave the way for innovative treatment options.
